Plain-English translation of NCT05761314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a research study for people who have been diagnosed with a RASopathy—a rare genetic condition that affects how cells grow and develop in the body. The researchers want to understand how often solid tumors (cancers that form in organs and tissues) occur in people with these conditions, and they will analyze tumor tissue samples to learn more about what causes these tumors to develop.
People with certain rare genetic syndromes appear to have a higher chance of developing solid tumors, but doctors don't yet fully understand why or how often this happens. This study aims to fill that gap so that doctors can better protect and monitor patients with these conditions.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will review your medical records and ask about your health history. If you have had a solid tumor, they may ask to obtain or analyze a tissue sample from that tumor using advanced genetic testing. The study is being conducted at one medical center and is designed to gather information from about 100 people with these rare genetic conditions.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Italy
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment target
~100 participants
Started
October 2021
Primary completion
October 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chiara Leoni, MD, PhD
Fondazione Policlinico A. Gemelli, IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.